{"product_id":"ionispharma-pestle-analysis","title":"Ionis PESTLE Analysis","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMake Smarter Strategic Decisions with a Complete PESTEL View\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eOur PESTLE Analysis for Ionis reveals the external forces—regulatory shifts, R\u0026amp;D funding trends, market dynamics, and technological innovations—most likely to shape the company’s trajectory; buy the full report to access granular risk assessments and strategic recommendations tailored for investors and strategists.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eP\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eolitical factors\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDrug Pricing Legislation and Policy\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThe Inflation Reduction Act's drug pricing provisions are reshaping Ionis's US pricing strategy for orphan and specialty therapies; Medicare negotiation for selected drugs could affect peak-year revenues for late-stage assets—analyst models estimate potential revenue downside of 10–30% over a decade for high-priced launches. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGlobal Trade and Geopolitical Stability\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAs Ionis expands via partnerships in 2024–25, geopolitical tensions—e.g., a 12% rise in export controls across EU-Asia routes in 2024—threaten international trials and supply-chain timing, risking delayed patient enrollment and drug shipments. Political stability in key European and Asian markets, where Ionis reported 28% of 2025 guided revenue from partnerships, is critical for steady regulatory filings and launches. Trade policies on biotech exports and genetic data transfers, increasingly restricted post-2023, remain a core strategic risk for commercialization.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGovernment Healthcare Funding\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003ePublic funding, notably NIH's $46.8 billion FY2024 budget, underpins biomedical research and supplies grants that catalyze early-stage innovation feeding Ionis's pipeline.\u003c\/p\u003e\n\u003cp\u003eShifts in U.S. healthcare spending priorities—Congressional debates over Medicare\/Medicaid funding and R\u0026amp;D appropriations—can accelerate or constrain grant availability and preclinical discovery timelines.\u003c\/p\u003e\n\u003cp\u003eIonis gains from policies favoring domestic leadership in genomic medicine, evident in increased federal investments and bipartisan support for advanced therapeutics commercialization.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRegulatory Agency Leadership\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eAppointments at FDA and EMA shape flexibility for accelerated approvals in rare diseases; since 2024 new FDA leadership increased advisory committee engagement, with FDA rare pediatric disease designations rising 12% in 2024 versus 2023.\u003c\/p\u003e\n\u003cp\u003eShifts in political leadership can tighten safety requirements or delay reviews; average FDA review times for biologics were 8.4 months in 2024, affecting Ionis timelines for antisense candidates.\u003c\/p\u003e\n\u003cp\u003eIonis depends on predictable, science-driven regulation—stable agency leadership and pathways like FDA accelerated approval or EMA PRIME are critical to commercializing its pipeline and revenue projections.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e2024 FDA rare pediatric designations +12% year-over-year\u003c\/li\u003e\n\u003cli\u003eAverage FDA biologic review time 8.4 months (2024)\u003c\/li\u003e\n\u003cli\u003eReliance on accelerated\/PRIME pathways for faster market entry\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePublic Health Policy and Pandemics\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eGovernment shifts during COVID-19 saw infectious disease funding rise by over 40% in 2020–2022, diverting grants from rare disease programs and potentially delaying Ionis trials and milestone revenues linked to partnered programs.\u003c\/p\u003e\n\u003cp\u003eMandates like the US CHIPS-style incentives for domestic pharma production and EU industrial policies could force Ionis to reassess manufacturing siting, raising CAPEX by an estimated 10–20% for onshoreization.\u003c\/p\u003e\n\u003cp\u003ePolicy moves toward preventative genomic medicine (projected market CAGR ~12% through 2028) expand demand for RNA-targeted therapies, creating long-term commercial upside for Ionis’ antisense platform.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eInfectious-disease funding +40% (2020–2022) redirected resources\u003c\/li\u003e\n\u003cli\u003eOnshoring could add 10–20% CAPEX to manufacturing\u003c\/li\u003e\n\u003cli\u003ePreventative genomic market CAGR ~12% to 2028 boosting RNA therapy demand\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDrug-pricing cuts, export risks, and faster biologic reviews reshape biotech returns\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eDrug-pricing reforms (IRA Medicare negotiation) could cut peak revenue 10–30% for high-price launches; export controls rose ~12% in 2024, risking trial\/supply timing; NIH FY2024 $46.8B supports early R\u0026amp;D; FDA biologic review avg 8.4 months (2024) with rare pediatric designations +12% YoY, influencing accelerated-pathway timelines.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eNIH FY2024\u003c\/td\u003e\n\u003ctd\u003e$46.8B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFDA biologic review (2024)\u003c\/td\u003e\n\u003ctd\u003e8.4 months\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRare pediatric designations 2024\u003c\/td\u003e\n\u003ctd\u003e+12% YoY\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eExport controls change 2024\u003c\/td\u003e\n\u003ctd\u003e+12%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePotential IRA revenue downside\u003c\/td\u003e\n\u003ctd\u003e10–30%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eExplores how external macro-environmental factors uniquely affect Ionis across six dimensions—Political, Economic, Social, Technological, Environmental, and Legal—backed by current data and trends to identify risks and opportunities for executives and investors.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eConcise, visually segmented PESTLE insights for Ionis that can be dropped into presentations or planning sessions to quickly align teams on external risks and market positioning.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eE\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003economic factors\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eInterest Rates and Capital Access\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAs of late 2025, the US Fed funds rate near 5.25%–5.50% raises Ionis Therapeutics’ effective cost of capital, tightening financing for R\u0026amp;D-heavy biotech firms and encouraging conservative burn rates.\u003c\/p\u003e\n\u003cp\u003eHigher rates shift focus to non-dilutive funding; Ionis increasingly pursues milestone-driven partnerships and licensing deals to preserve equity—investor models assume lower equity raises and track cash runway against ~$500M+ pipeline spend needs.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCurrency Exchange Volatility\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eIonis earns royalties worldwide and is exposed to FX swings; in 2024 roughly 35–45% of partner revenues tied to its IP were in non‑USD currencies, so a stronger dollar can materially lower reported payouts from partners like Biogen and AstraZeneca.\u003c\/p\u003e\n\u003cp\u003eIn 2024 Ionis reported using hedging programs and allocating ~40% of clinical trial spend outside the US to naturally hedge operational costs, reducing net FX exposure.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eInflation and Operational Costs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003ePersistent inflation in 2024–2025 has pushed lab equipment and oligonucleotide reagent costs up an estimated 6–9% year-over-year, while median biotech R\u0026amp;D salaries rose ~8% in 2024, increasing Ionis’s input and labor expenses.\u003c\/p\u003e\n\u003cp\u003eHigher operational costs risk compressing gross margins and EBITDA unless offset by milestone payments—Ionis reported $615m cash used in operations in 2024, making revenue-generating launches critical.\u003c\/p\u003e\n\u003cp\u003eEffective burn-rate management is essential: with $1.3bn cash and equivalents at end-2024, Ionis must control spend to preserve strategic independence amid rising costs.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBiotech Sector Investment Trends\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eThe biotech market expanded to about $1.6T in 2024 with platform-focused names outperforming; investor appetite lifted platform valuations by ~25% vs. peers in 2023–24, improving Ionis’s strategic optionality.\u003c\/p\u003e\n\u003cp\u003eRisk-on cycles historically raised biotech deal values and R\u0026amp;D multiples; during 2022–23 downturns, firms shifted to late-stage prioritization—Ionis trimmed discovery spend by ~10–15% in similar phases to conserve cash.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e2024 biotech market ~$1.6T; platform valuations up ~25% in 2023–24\u003c\/li\u003e\n\u003cli\u003eRisk-on periods boost R\u0026amp;D multiples and M\u0026amp;A activity\u003c\/li\u003e\n\u003cli\u003eDownturns force reallocation to late-stage assets; ~10–15% discovery cuts observed\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHealthcare Payer Reimbursement Models\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eEconomic pressures on private and public insurers are driving stricter value-based reimbursement for costly gene-based therapies; in the US, specialty drug spend reached 52% of total drug costs in 2023, pressuring coverage decisions.\u003c\/p\u003e\n\u003cp\u003eIonis must supply robust clinical utility and cost-effectiveness evidence—payers often require quality-adjusted life year thresholds around $100,000–$150,000—to secure formulary placement.\u003c\/p\u003e\n\u003cp\u003eThe healthcare system’s capacity to absorb high-cost specialty medicines remains a major hurdle: global orphan\/gene therapy launches saw average launch prices exceeding $1 million in recent years, prompting utilization management and outcomes-based contracts.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eSpecialty drugs = 52% of US drug spend (2023)\u003c\/li\u003e\n\u003cli\u003eCommon payer QALY thresholds: $100k–$150k\u003c\/li\u003e\n\u003cli\u003eAverage gene therapy launch prices \u0026gt; $1M, driving outcomes-based contracts\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRising US rates squeeze Ionis R\u0026amp;D as cash runway tightens amid booming $1.6T biotech\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eHigher US rates (5.25–5.50% late‑2025) raise Ionis’s WACC, tightening R\u0026amp;D funding; 2024 cash $1.3B, ops cash burn $615M; 2024 biotech market ~$1.6T, platform valuations +25% (2023–24); specialty drugs 52% of US drug spend (2023); payer QALY thresholds $100k–$150k; gene therapy launches \u0026gt;$1M driving outcomes-based deals.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eFed funds rate\u003c\/td\u003e\n\u003ctd\u003e5.25–5.50% (late‑2025)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eIonis cash\u003c\/td\u003e\n\u003ctd\u003e$1.3B (end‑2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e2024 cash burn\u003c\/td\u003e\n\u003ctd\u003e$615M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eBiotech market\u003c\/td\u003e\n\u003ctd\u003e$1.6T (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePlatform val change\u003c\/td\u003e\n\u003ctd\u003e+25% (2023–24)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSpecialty drug share\u003c\/td\u003e\n\u003ctd\u003e52% (US, 2023)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003ePreview the Actual Deliverable\u003c\/span\u003e\u003cbr\u003eIonis PESTLE Analysis\u003c\/h2\u003e\n\u003cp\u003eThe preview shown here is the exact Ionis PESTLE Analysis you’ll receive after purchase—fully formatted, professionally structured, and ready to use.\u003c\/p\u003e\n\u003cp\u003eNo placeholders or teasers: the content, layout, and structure visible in the preview are the final file you’ll be able to download immediately after payment.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"MatrixBCG","offers":[{"title":"Default Title","offer_id":56751893938553,"sku":"ionispharma-pestle-analysis","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0911\/3554\/1625\/files\/ionispharma-pestle-analysis.png?v=1772235832","url":"https:\/\/matrixbcg.com\/products\/ionispharma-pestle-analysis","provider":"MatrixBCG","version":"1.0","type":"link"}